Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Medical College of Wisconsin · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
carcelltherapy
refractory multiple myeloma, relapse multiple myeloma, car-t, chimeric antigen receptor t-cell therapy, car therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 872216
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.